Biocon Biologics

YESINTEK recommended for approval to treat psoriasis, psoriatic arthritis, and Crohn’s disease in adults and children

The biosimilar Ustekinumab-kfce is set for commercialisation in the US by February 2025 under a licensing agreement with Janssen

The shortage of qualified healthcare professionals, coupled with the rising prevalence of diabetes, creates a critical health…

Over 50,000 global industry professionals, including key decision-makers, gathered at the event to explore new partnerships and…

This relates to the cGMP inspection conducted by the agency between February 20-28, 2024

This year’s ranking is based on a comprehensive web-based survey of about 6,400 respondents

Biocon Biologics' study identifies six policy recommendations to improve access to biosimilars in LMICs, addressing healthcare…

The Bonds are expected to be rated BB by both S&P and Fitch and will be listed on the Singapore Stock Exchange

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports…

Patent dispute settlement with Janssen clears path for biosimilar to Stelara in key global markets